Trials / Completed
CompletedNCT01085422
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assess whether the combination of ABT-888 with temozolomide (TMZ) has activity in subjects with metastatic castration resistant prostate cancer (CRPC) as reflected by the prostate-specific antigen (PSA) response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-888 | Subjects will be given ABT-888 on Days 1 -7 every 28 days orally and temozolomide on days 1-5 on days 1-5 every 28 days orally with ABT-888 |
| DRUG | temozolomide | Subjects will be given ABT-888 40 mg twice daily on Days 1 -7 every 28 days orally and temozolomide on days 1-5 every 28 days orally with ABT-888 |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2010-03-11
- Last updated
- 2017-11-21
Source: ClinicalTrials.gov record NCT01085422. Inclusion in this directory is not an endorsement.